The ISCTM 10th Anniversary Annual Scientific Meeting will be held in Washington, DC next week at The Fairmont Hotel. Industry experts will gather to share their research and new discoveries in CNS drug development. Bracket’s subject matter experts will be among those presenting their recent findings.
Working Group Dinner Session
The Working Group Dinner Sessions will take place on Tuesday, February 18, from 7:00 – 9:00pm.
Gary Sachs, M.D., Bracket’s Therapeutic Area Leader for bipolar disease and mood disorders, will be chairing a Working Group Dinner Session with Michael Detke, M.D., President of Detke Biopharma Consulting LLC. The session is titled: Implementing Innovation Working Group Dinner Session. The working group aims to deliver a paper with recommendations to help those seeking to implement innovation in CNS drug development. To learn more, click here.
The formal poster session will take place on Wednesday, February 19, from 6:00 – 8:00pm in Ballroom II. Below are the scientific posters in which Bracket subject matter experts are contributing authors.
The prevalence and nature of Mild Cognitive Impairment in Parkinson’s disease (PD-MCI) identified using different cognitive testing methodologies
Keith A. Wesnes, Ph.D. and Peter Annas, Ph.D.
Prospective Suicidal Ideation and Behavior Assessment: An Internet Survey of Pharmaceutical Sponsor Practices
ISCTM Suicidal Ideation and Behavior Assessment Working Group
Chappell, P (Pfizer) & Mahableshwarkar, A (Takeda) (Co-Chairs), Alphs, L (Janssen Scientific), Bangs, M (Lilly), Butler, A (Bracket), Dubrava, S (Phizer), Feltner, D (Abbvie), Greist, J (Healthcare Technology Systems), Harkavy-Friedman, J (American Foundation for Suicide Prevention), Lenderking, W (Evidera), Mundt, J (Center for Telepsychology), Palumbo, D (Pfizer), Stewart, M (Pfizer)
Risk Based Data Quality Monitoring Utilizing Data Analytics and Recorded PANSS Interviews in Global Schizophrenia Trials
David Daniel, M.D. and Alan Kott, M.D.
Concordance between Clinician and Centralized Computer Ratings in a Bipolar Maintenance Study of ELND005 (Scyllo-inositol)
Matthias Kurth (Elan Pharmaceuticals), Gerald Crans (Elan Pharmaceuticals), Menghis Bairu (Elan Pharmaceuticals, Gary Sachs (Dept of Psychiatry, Massachusetts General Hospital and Bracket), and Susan Abushakra (Elan Pharmaceuticals)
You can find the full agenda here.